KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Deferred Taxes (2016 - 2017)

Travere Therapeutics' Deferred Taxes history spans 4 years, with the latest figure at $1.4 million for Q4 2017.

  • For Q4 2017, Deferred Taxes rose 111.88% year-over-year to $1.4 million; the TTM value through Sep 2018 reached $1.4 million, up 107.12%, while the annual FY2017 figure was -$6.4 million, 71.65% up from the prior year.
  • Deferred Taxes reached $1.4 million in Q4 2017 per TVTX's latest filing, up from -$2.4 million in the prior quarter.
  • In the past five years, Deferred Taxes ranged from a high of $28.2 million in Q3 2015 to a low of -$40.0 million in Q1 2015.
  • Average Deferred Taxes over 4 years is -$3.9 million, with a median of -$2.9 million recorded in 2014.
  • The largest YoY upside for Deferred Taxes was 111.88% in 2017 against a maximum downside of 285.78% in 2017.
  • A 4-year view of Deferred Taxes shows it stood at -$2.5 million in 2014, then tumbled by 53.74% to -$3.8 million in 2015, then tumbled by 208.36% to -$11.7 million in 2016, then surged by 111.88% to $1.4 million in 2017.
  • Per Business Quant, the three most recent readings for TVTX's Deferred Taxes are $1.4 million (Q4 2017), -$2.4 million (Q3 2017), and -$3.4 million (Q2 2017).